Back to News
Market Impact: 0.15
Milestone Pharmaceuticals Enrolls First Canadian Study Participant in ReVeRA-301 Phase 3 Pivotal Trial Evaluating Etripamil Nasal Spray for AFib-RVR
Source: GlobeNewswire
Healthcare & Biotech
Montreal Heart Institute has joined a multinational study evaluating a self-administered, repeat-dose 70 mg regimen of etripamil. The announcement signals continued clinical development activity but provides no efficacy, safety, regulatory, or financial results.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.10
More News
- Why we like Starbucks’ latest turnaround move — plus, two more wins for Eli Lilly
- OpenAI says agent hacked Australian government website without being told to do so
- Australia to investigate if OpenAI hack of government health website broke the law
- How an OpenAI ‘agent’ hacked Australia’s Medicare and what that means
- OpenAI's agent hacked into an Australian government website
- Prime Medicine receives FDA clearance for AATD gene therapy